Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Human and rabbit plasma contain a cholesteryl ester transfer protein (CETP) that promotes net mass transfers of cholesteryl esters from high density lipoproteins (HDL) to other plasma lipoprotein fractions. As predicted, inhibition of CETP in both humans and rabbits increases the concentration of cholesterol in the potentially protective HDL fraction, while decreasing it in potentially proatherogenic non-HDL fractions. Inhibition of CETP in rabbits also inhibits the development of diet-induced atherosclerosis. However, use of the CETP inhibitor torcetrapib in humans did not reduce atheroma in three imaging trials and caused an excess of deaths and cardiovascular events in a large clinical outcome trial. The precise explanation for the harm caused by torcetrapib is unknown but may relate to documented, potentially harmful effects unrelated to inhibition of CETP. More recently, a trial using the weak CETP inhibitor dalcetrapib, which raises HDL levels less effectively than torcetrapib and does not lower non-HDL lipoprotein levels, was terminated early for reasons of futility. There was no evidence that dalcetrapib caused harm in that trial. Despite these setbacks, the hypothesis that CETP inhibitors will be antiatherogenic in humans is still being tested in studies with anacetrapib and evacetrapib, two CETP inhibitors that are much more potent than dalcetrapib and that do not share the off-target adverse effects of torcetrapib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · cited 1×
“decreases the risk of having a CV event (2).”
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 8×
“cholesterol in the group receiving torcetrapib, the trial was terminated early because of a statistically significant excess of deaths associated with treatment with torcetrapib (30).”
InfluentialSelf-citationMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · cited 1×
“as an independent predictor of CV risk (1).”
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“still no direct evidence from clinical outcome trials in humans that raising the level of HDL cholesterol will translate into a reduction in clinical CV events, there is a large and compelling body of evidence in animal studies (5) (6) ;(7) (8) and growing evidence in human studies (9) (10), that HDL-raising therapies…”
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610 · cited 1×
“LDL cholesterol has been decreased to very low levels by treatment with statins (3).”
Self-citationPlasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 5×
“effect on blood pressure, aldosterone or serum electrolytes in humans (31) and does not stimulate the synthesis of aldosterone in adrenal cortical cells growing in tissue culture (69).”
InfluentialSelf-citationHigh-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., Thomas, W. G., Mukhamedova, N., de Courten, B., Forbes, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843219 · Cited by 443
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · cited 3×
“with CETP inhibitor drugs (30) (31) (32) (33) increases the concentration of both HDL cholesterol and apoA-I (the major apolipoprotein in HDLs) and in some cases also decreases the concentration of LDL cholesterol and apoB (the main”
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Self-citation
Cited by
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Laslett, L. J., Alagona, P., Clark, B. A., Drozda, J. P., Saldivar, F., Wilson, S. R., Poe, C., & Hart, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.002 · Cited by 768
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Self-citationSchwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.91 · Cited by 264
Metadata
- Authors
- Barter, P. J., & Rye, K.-A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 53
- Issue
- 9
- Pages
- 1755-1766
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2009220054
- Cited by
- 146
- References
- 10
- FWCI
- 22.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. https://app.cochat.ai/papers/10.1194/jlr.r024075
- The paper
- Barter, P. J., & Rye, K.-A. (2012). Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research. https://doi.org/10.1194/jlr.r024075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.